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Abstract
Background: Conventional post-mastectomy radiation therapy is delivered with tangential fields for chest wall and
separate fields for regional nodes. Although chest wall and regional nodes delineation has been discussed with
RTOG contouring atlas, CT-based planning to treat chest wall and regional nodes as a whole target has not been
widely accepted. We herein discuss the dosimetric characteristics of a linac IMRT technique for treating chest wall
and regional nodes as a whole PTV after modified radical mastectomy, and observe acute toxicities following
irradiation.
Methods: Patients indicated for PMRT were eligible. Chest wall and supra/infraclavicular region +/−internal
mammary nodes were contoured as a whole PTV on planning CT. A simplified linac IMRT plan was designed using
either integrated full beams or two segments of half beams split at caudal edge of clavicle head. DVHs were used
to evaluate plans. The acute toxicities were followed up regularly.
Results: Totally, 85 patients were enrolled. Of these, 45 had left-sided lesions, and 35 received IMN irradiation.
Planning designs yielded 55 integrated and 30 segmented plans, with median number of beams of 8 (6–12).
The integrated and segmented plans had similar conformity (1.41±0.14 vs. 1.47±0.15, p=0.053) and homogeneity
indexes (0.13±0.01 vs. 0.14±0.02, p=0.069). The percent volume of PTV receiving >110% prescription dose was <5%.
As compared to segmented plans, integrated plans typically increased V5 of ipsilateral lung (p=0.005), and heart
(p=0.001) in patients with left-sided lesions. Similarly, integrated plans had higher spinal cord Dmax (p=0.009),
ipsilateral humeral head (p<0.001), and contralateral lung Dmean (p=0.019). During follow-up, 36 (42%) were
identified to have ≥ grade 2 radiation dermatitis (RD). Of these, 35 developed moist desquamation. The median
time to onset of moist desquamation was 6 (4–7) weeks from start of RT. The sites of moist desquamation
were most frequently occurred in anterior axillary fold (32/35), and secondly chest wall (12/35). The difference
in occurrence of ≥ grade 2 RD between integrated and segmented plans was statistically insignificant
(X2=0.35, p=0.55). Only 2 were found to have grade 2 radiation pneumonitis.
Conclusions: The linac IMRT technique applied in PMRT with chest wall and regional nodes as a whole PTV was
dosimetrically feasible, and the treatment was proved to be well-tolerated by most patients.
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Background
Although the utilization of breast conserving surgery
(BCS) for early-stage disease has increased rapidly in last
decade in mainland China, modified radical mastectomy
(MRM) remains the most-accepted surgical modality in
operable breast cancer [1]. Three randomized clinical
trials have shown that a disease-free and overall survival
advantage is conferred by the addition of chest wall and
regional lymph node irradiation in women with positive
axillary lymph nodes after MRM [2-4].
Conventional post-mastectomy radiation therapy (PMRT)
is often delivered with traditional field borders for chest
wall and regional nodes. Although chest wall and regional
nodes delineation techniques have been discussed with
available contouring guidelines, computed tomography
(CT)-based planning to treat chest wall and nodal regions
as a whole PTV has not yet been adopted into routine
practice. We herein discuss the dosimetric characteristics
of an inverse-planned intensity-modulated radiation ther-
apy (IMRT) technique for total local-regional irradiation




Eligibility criteria included: (1) age ≥ 18 years with oper-
able breast cancer involving axillary lymph nodes, but
without evidence of distant metastasis (negative results on
chest CT scans, abdomen and pelvis US); (2) resection of
all gross disease by MRM with level I to II axillary dissec-
tion; (3) negative surgical margins; (4) Eastern Cooperative
Oncology Group performance score of 0–1; (5) comple-
tion of adjuvant chemotherapy; and (6) no previous thor-
acic RT. Patients with serious comorbid diseases, such as
chronic obstructive pulmonary disease, connective tissue
disease, postoperative wound infections, and delayed
wound healing, etc., that would have negatively affected
their tolerance to radiation-induced skin or lung toxicity
were not eligible. Patients with synchronous bilateral
breast cancers were eligible. All patients provided written
informed consent.
Study design
There were two parts to this study. The first part was to
discuss dosimetric characteristics of a PMRT method,
which would treat chest wall and regional nodes as a whole
PTV with linac IMRT technique (dosimetric study). And
the second part was to evaluate acute toxicities following
PMRT with total local-regional IMRT (clinical study).
Dosimetric study
Images acquisition
Before simulation, the patient was placed supine on a
commercially available breast tilt board (Med-Tech 350)
to make sternum parallel to the table, with both arms
fully abducted (90 degrees or greater) and externally ro-
tated, and head position secured. A planning CT scan at
5-mm intervals from mid-neck to diaphragm with no
contrast enhancement was obtained for each patient
using an AcQsim CT simulator (Philips Medical Sys-
tems). At simulation, the mastectomy scar was routinely
wired with radiopaque markers.
Contours definition
The clinical target volumes (CTV) were defined to con-
sist of ipsilateral chest wall, mastectomy scar, and supra/
infraclavicular region for each patient. Treatment of in-
ternal mammary nodes (IMN) was strongly considered
when primary tumor was located in central or medial
part of the breast. Each CTV was delineated according
to the breast cancer atlas for radiation therapy planning
consensus definitions of the Radiation Therapy Oncol-
ogy Group (RTOG) (available at: http://www.rtog.org/
CoreLab/ContouringAtlases/BreastCancerAtlas.aspx). The
borders of CTV for chest wall and regional nodes were
described in Table 1. The chest wall CTV was expanded
1 cm to become chest wall PTV, except that anterior,
posterior and cranial borders were unchanged. This
modification was made mainly to account for build-up
region or spare underling normal lung from high dose
radiation [5,6]. If IMN irradiation not indicated, medial
border of chest wall PTV was usually at medial edge of
sternal-rib junction (with reference to medial border of
contralateral breast). The anatomically based guidelines
established by Dijkema et al. [7] were also referenced
when regional node CTVs were contoured. Generally,
expansions of 5 mm to CTV for supra/infraclavicular
nodes and 7 mm to CTV for IMN were made to form
the PTV for supra/infraclavicular nodes and IMN, re-
spectively. If IMN included, PTV for IMN would be
smoothly integrated into PTV for chest wall. The PTV
for supra/infraclavicular nodes would match the PTV for
chest wall, and IMN if indicated, at the clavicle head in-
feriorly. As a result, a whole PTV including both chest
wall and regional nodes formed.
The organs at risk (OARs) surrounding the targets, in-
cluding bilateral lungs, heart, contralateral breast, ipsilat-
eral humeral head, spinal cord, and esophagus, were
contoured as well. The heart was defined as from its apex
to the junction of great vessels with myocardium, and
esophagus was contoured from cricoid cartilage to cardia.
In addition, the healthy tissue was defined as the patient’s
volume covered by the CT scan minus the envelope of the
PTV to account for the spillage of prescription dose.
Plan optimization
For each patient, a multi-beam simplified IMRT plan was
generated using Pinnacle treatment planning software
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(version 8.0). The IMRT plans were designed using either
integrated full beams or two segments of half beams split
at caudal edge of clavicle head, the latter technique require
that the length of chest wall PTV should not exceed
19 cm so as to be fully covered by the half beams at caudal
side. Although the selection of beam angles was at discre-
tion of the responsible dosimetrist, basically, an integrated
plan employs full beam to cover the whole PTV, whereas a
segmented plan uses different beam angles in the cranial
half beams to cover the upper part of PTV (supra/
infraclavicular region), and caudal half beams to cover the
lower part (chest wall±IMN), respectively. The angles sec-
tors covered by multiple beams are shown in Figures 1
and 2 for representative integrated and segmented plans,
respectively. All plans were optimized to cover the whole
PTVs and spare surrounding normal tissues as much as
possible. To ensure a sufficient skin dose, a daily 3-mm
bolus was placed on chest wall of each patient. The
optimization process started with dose-volume constraints
as follows: 90% of PTV to receive 50Gy in 25 fractions; ip-
silateral mean lung dose ≤20Gy, and ≤30% of the ipsilat-
eral lung to receive ≤20Gy; ≤5% of the heart to receive
≤30Gy, mean heart dose ≤8Gy for left-sided lesions, and
≤10Gy if IMN was included; spinal cord maximum dose
≤45Gy; contralateral breast mean dose ≤1.5Gy. Priority
was high for the PTV, heart and lung constraints relative
to other structures. Optimization proceeded with these
settings until no further improvement was seen. Priority
was then increased for other structures until a balance
was reached between PTV coverage and normal tissues
sparing. During optimization, a simplified IMRT plan was
defined to have ≤5 segments/beam, ≥ 10 cm2/segment,
and ≥10 MU/segment [8]. After optimization, a final dose
calculation using the collapsed cone convolution super-
position (CCCS) algorithm was performed. Dose grid size
used for calculations was 0.2 cm by 0.2 cm by 0.2 cm.
Once PTV and normal tissues dose constraints were met,
the dosimetrist would expand the anterior border of chest
wall field 1.5-2 cm beyond the skin surface to ensure chest
wall coverage.
Plan evaluation
For dosimetric analysis, the following indices extracted
from dose-volume histograms (DVHs) were used: 1)
Dnear-max, Dnear-min, and Dmean for PTV: Dnear-max is de-
fined to be the dose to the 2% of the PTV (D2%),
Dnear-min is the dose to the 98% of the PTV (D98%), and
Dmean is the mean dose to the PTV; 2) V95%, V107% and
V110% for PTV: percent volume receiving greater than
95% to 110% of prescribed dose; 3) dose homogeneity
index (HI) and conformity index (CI) for PTV: HI and
CI were calculated according to definition proposed by
the International Commission on Radiation Units and
Measurements (ICRU) [9] and expressed as follows:
HI ¼ D2%D98%D50%  100% and CI ¼ Precription Isodose VolumeTarget Volume ,
lower HI and CI correlate with a more homogeneous target
dose and better conformity, respectively; 4) ipsilateral lung
V5, V20, and Dmean; contralateral lung V5 and Dmean; heart
V5, V10, V20, V30, Dmean; spinal cord Dmax; ipsilateral hu-
meral head Dmean; esophagus Dnear-max and Dmean; contra-
lateral breast V5 and Dmean; 5) external volume index (EI)
for healthy tissue [10]: EI is defined as Vhealthy tissue/VPTV
where Vhealthy tissue is the volume of healthy tissue receiving
more than 50Gy and VPTV is the volume of the total PTV.
Clinical study
All treatments were delivered with 6-MV photon using
an Electa linear accelerator. To ensure accurate delivery
of each IMRT plan, orthogonal megavoltage electronic
portal images were captured once before the first treat-
ment and per week thereafter, and compared with refer-
ence digitally reconstructed radiographs (DRRs) to verify
patient position. Each patient was regularly followed up
by the treating physician once a week during radiother-
apy and after irradiation. Radiation dermatitis (RD) was
Table 1 Anatomic borders of CTV for chest wall and regional nodes
Structures Cranial Caudal Anterior Posterior Lateral Medial
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checked up to 1 month after the completion of treatment.
The occurring time and site of most serious radiation
dermatitis were recorded for each patient. Radiation pneu-
monitis (RP) was assessed within 6 months. All acute side
effects were graded according to the common terminology
of criteria for adverse effects (CTCAE v4.0) issued by the
National Cancer Institutes.
Statistical analysis
The independent two-sample t-test was used to compare
the dosimetric parameters between plans. Chi-square
test was used to see the statistical significance of the dif-
ference in the occurrence of ≥grade 2 RD between inte-
grated and segmented plans. p values of ≤ 0.05 were
considered statistically significant.
Results
Between June 2009 and Oct 2010, 87 patients were ran-
domly enrolled onto the study and 85 patients (median
age of 50 (28–69)) met eligibility for analysis. Of these,
there were 45 cases with left-sided breast cancer, and 35
received IMN irradiation, including 19 left-sided lesions.




The median number of beams applied was 8 (range 6–12)
for all patients. Of their plans, 55 were integrated, and 30
were segmented. The median number of beams was 7
(range 6–10) for integrated plans and 10 (range 8–12) for
segmented plans which included 4 (range 3–6) beams for
upper segments and 6 (range 4–7) beams for lower
segments. The average of total MUs per fraction was
829.7±197.2. The number of MUs was significantly
lower for integrated plans compared with segmented
plans (728.9±111.3 vs. 1014.5±187.9, p<0.001).
Target coverage and homogeneity
Table 2 summarized the results of PTV dosimetry. In
comparison with integrated plans, segmented plans had
higher Dnear-max, Dmean, V107%, and V110%; however, their
dose conformity and homogeneity were similar. In
addition, the V110% was generally <5%, indicating that a
Figure 1 A 7-beam integrated plan designed for a patient with left breast cancer: (a) beam angles (115, 125,135, 300, 315, 330, and
345 degrees) for supra/infraclavicular region; (b) identical beam angles for chest wall and IMN; (c): lateral beam’s-eye-view (BEV) of the
whole PTV with multi-leaf collimator (MLC)-defined port displayed.
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very small volume of PTV received >110% of prescrip-
tion dose. The inclusion of IMN in PTV didn’t com-
promise the target coverage and dose homogeneity.
OARs and healthy tissue
Table 3 listed the dose-volume statistics of OARs and
healthy tissue. All IMRT plans were clinically acceptable
regarding the dose-volume of lung, heart, spinal cord, and
contralateral breast irradiated. As compared to segmented
plans, integrated plans typically increased V5 of ipsilateral
lung (p=0.005), and heart (p=0.001) in patients with left-
sided lesions. Also, integrated plans had higher spinal cord
Dmax (p=0.009), Dmean of ipsilateral humeral head
(p<0.001), and Dmean of contralateral lung (p=0.019).
Doses to other OARs, such as esophagus Dnear-max and
contralateral breast Dmean, were higher in integrated plans,
although the differences did not reach statistical signifi-
cance. In addition, compared to integrated plans, seg-
mented plans reduced EI for healthy tissue.
Clinical data
All patients finished treatment per protocol. At up to 6 -
months of follow-up, 36 (42%) patients in total were
identified to have ≥ grade 2 RD. Of these, 24 (28%) had
grade 2, 12 (14%) had grade 3 RD, and 35 developed
moist desquamation. The median time to the onset of
moist desquamation was 6 (4–7) weeks from start of RT,
and mostly occurred within 1–2 weeks after completion
of treatment. The sites of moist desquamation were most
frequently occurred in anterior axillary fold (32/35), and
secondly in chest wall (12/35). Nine patients had moist
desquamation in both anterior axillary fold and chest wall.
All the area of moist desquamation occurred where bolus
was applied. None was observed at the sites where moist
desquamation most frequently occurred with conventional
technique, i.e., the junction of chest wall tangents and
IMN/SC field. The difference in the occurrence of ≥grade
2 RD between integrated (22/55) and segmented plans
(14/30) was statistically insignificant (X2=0.35, p=0.55). In
addition to RD, 23 (27%) patients experienced grade 2
swallowing pain. Only 2 (2.3%) patients were found to
have grade 2 RP. No other severe acute toxicities
were observed.
Discussion
The conventional PMRT technique generally includes two
opposed tangential photon beams for chest wall, and sep-
arate anterior fields for regional nodes with mixed
Figure 2 A 10-beam segmented plan designed for a patient with right breast cancer: (a) 4 beams (0, 35, 215, and 330 degrees)
for supra/infraclavicular region; (b) six beams (35, 45, 55, 220, 235, and 245 degrees) for chest wall; (c): lateral BEV of the PTV with
MLC-defined port displayed.
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photon-electron beams. This technique has several disad-
vantages. First, the tissue between the chest wall and
supraclavicular region +/− IMN may be under or
overdosed, because of the junction or overlap between the
tangents and anterior fields, therefore potentially increas-
ing normal tissues toxicities or reducing tumor control
probability. Although many ways have been reported to be
able to address the junction issue between chest wall and
supraclavicular region [11,12], it’s difficult to eliminate the
overlap between chest wall and IMN with geometric
matching method. Second, the use of mixed beams for re-
gional nodes may be associated with inhomogeneous dose
distribution. In addition, the maximum depth of supra/
infraclavicular region varied with patients’ anatomy [13]
and body mass index (BMI) [14]; routine use of mean
depth did not optimally cover intended targets for every
patient, and might also result in overdose to some normal
tissues in a portion of patients.
Recently, optimized CT-based treatment planning has
been explored and found to offer better coverage of supra/
infraclavicular targets than the empirically derived dose
prescription that are commonly used, in Liengsawangwong’
dosimetric study [14]. The other study carried out by
Krueger et al. [15] showed that a nine-field IMRT tech-
nique applied in patients receiving PMRT improved the
coverage of chest wall and regional nodes while
maintaining similar doses to heart and ipsilateral lung as
conventional techniques. To further prove the feasibilities
of inverse IMRT plans for PMRT in both dosimetric and
clinical aspects, we therefore initiated this study to develop
a linac IMRT technique with chest wall and regional nodes
as a whole PTV, and to treat post-mastectomy breast can-
cer patients using this technique.
Dosimetric characteristics of linac IMRT PMRT
In dosimetric part of this study, the IMRT technique
treating chest wall, supra/infraclavicular region, +/−IMN
as a whole PTV was established by creating integrated or
segmented plans for 85 patients after MRM. Both inte-
grated and segmented plans were found to have adequate
but similar PTV dose homogeneity and conformity. The
percent volume of PTV receiving ≥110% of prescription
dose was negligible and scattered in whole PTV. As an ex-
ample, Figure 3 represents a direct comparison of dose
distribution between IMRT and conventional plans. Hot
spots and field junction issues associated with separate
fields for regional nodes were basically eliminated.
Although conventional PMRT technique based on
clinical target definition has been found to undertreat
certain portion of target volume defined by RTOG or
other contour guidelines [6], there has been no consen-
sus whether new complex techniques to treat regional
nodes and chest-wall as a whole PTV should become
new standard replacing the traditional field design. As
the target volume defined by CT-based contour are lar-
ger than that with clinical definition, undesired high
dose to normal tissues is the major concern if dose con-
straints to normal tissue are not properly defined. As
Fontanilla et al. [6] recently reported, when contour-
based treatment plans were designed with traditional
four fields without IMRT optimization, there exists an
important increase in dose to the normal tissues. With a
prescription dose of 50Gy, the mean ipsilateral lung V20
was 32% and 45% in left-sided and right-sided patients
respectively [6]. This is slightly different to V20 reported
at 28% in the current study. Rudat et al. [5] also found
that tangential beam IMRT for irradiation of the chest
wall of postmastectomy breast cancer patients could sig-
nificantly decrease the dose-volume of the ipsilateral
lung, and in patients with left-sided cancer the dose-
volume of the heart compared to tangential beam 3D-
CRT of the chest wall with the same target definitions,
however, dose to the regional nodes was not evaluated.
Treatment of the regional nodes and especially the
Table 2 Summary of DVH-based analysis for the PTV
Parameters Plans Value (Mean±SD) P-value
Dnear-max (Gy) All 54.76±0.97
Integrated 54.57±0.88 0.047
Segmented 55.01±1.05
Dnear-min (Gy) All 47.53±0.63
Integrated 47.56±0.70 0.622
Segmented 47.48±0.47


















Abbreviations: PTV: planning target volume; Dnear-max: maximum dose; Dnear-min:
minimum dose; Dmean: mean dose; CI: conformity index; HI: homogeneity
index; Vx%: percent volume of PTV receiving x% of prescription dose; IMN:
internal mammary nodes.
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Table 3 Summary of DVH-based analysis for OARs and healthy tissue
Organ/Structure Parameters Plans Value (Mean±SD) P-value






Dmean (Gy) All 15.06±1.66
Integrated 15.11±1.54 0.658
Segmented 14.93±1.99
Contralateral lung V5 All 12%±11%
Integrated 14%±12% 0.157
Segmented 9%±8%
Dmean (Gy) All 2.26±1.32
Integrated 2.58±1.43 0.019
Segmented 1.66±0.83
Heart V5 Left-sided lesions 56%±15%
Integrated 60%±13% 0.001
Segmented 45%±13%
V10 Left-sided lesions 30%±9%
Integrated 31%±10% 0.076
Segmented 26%±7%
V20 Left-sided lesions 13%±6%
Integrated 14%±7% 0.77
Segmented 13%±4%
V30 Left-sided lesions 7%±3%
Integrated 8%±4% 0.21
Segmented 6%±3%
Dmean (Gy) Left-sided lesions 8.69±1.47
Integrated 8.76±1.61 0.65
Segmented 8.54±1.14
Spinal cord Dmax (Gy) All 36.10±5.87
Integrated 37.24±4.55 0.009
Segmented 33.29±7.97
Ipsilateral humeral head Dmean (Gy) All 23.98±9.25
Integrated 28.22±5.60 <0.001
Segmented 12.31±6.99
Esophagus Dnear-max (Gy) All 41.56±7.79
Integrated 41.84±9.15 0.85
Segmented 41.29±6.47
Dmean (Gy) All 11.14±3.11
Integrated 11.22±2.78 0.745
Segmented 10.83±4.27
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IMNs increase the complexity of RT planning and deliv-
ery, and with certain techniques, may increase the risks
of cardiac and pulmonary toxicity [16]. Thus, it is crucial
to establish optimal IMRT techniques minimizing expos-
ure to normal tissues and maintaining reasonable target
coverage, and at least have well-defined dose constraints
to normal tissue with prioritization in certain normal tis-
sue when target volume coverage cannot be fully met. In
the current study, both integrated and segmented IMRT
plans showed reasonable normal tissue dose, while seg-
mented IMRT plans conferred lower dose to nearby
structures, such as contralateral lung, ipsilateral humeral
head, and spinal cord, than integrated plans. This is
largely attributed to the difference in beam selection for
chest wall (mostly tangents) and for supra/infraclavicular
nodes (with posterior-oblique ones). Hence, segmented
IMRT plans had potential to better spare the surround-
ing normal tissues even if the number of total beams
Table 3 Summary of DVH-based analysis for OARs and healthy tissue (Continued)






Healthy tissue EI All 0.30±0.04
Integrated 0.31±0.03 0.094
Segmented 0.28±0.05
Abbreviations: Vx: percent volume of critical structures receiving a dose of x Gy; EI: external volume index; other abbreviations as in Table 2.
Figure 3 A direct comparison of dose distribution between IMRT (b) and conventional plans (a): red line:55Gy; yellow line: 53.5Gy;
blue line: 45Gy; purple line: 30Gy; pink line: 20Gy; green line: 10Gy.
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increased slightly (median 10 instead of median 7 in in-
tegrated plans).
Toxicity profile following linac IMRT PMRT
Compared to the number of reports regarding IMRT
techniques in PMRT [15,17-20], the toxicity profile is
unclear in post-mastectomy breast cancer patients
treated with IMRT technique, and available data mainly
comes from patients treated with conventional tech-
niques. In clinical part of this study, most patients toler-
ated treatment well. As with previous reports, RD was
found to be the most common acute side effects follow-
ing PMRT. The frequency of ≥grade 2 RD was 42% for this
group of patients treated with IMRT technique, as com-
pared to 40-90% for patients treated with conventional
technique reported previously [21]. The occurring time to
most serious RD and sites of moist desquamation were
consistent with previous data as well. Although dosimetric
analyses demonstrated that segmented plans were superior
to integrated plans in the sparing of some nearby struc-
tures, especially the low dose volume of heart, ipsilateral
lung and contralateral lung, we did not observe any differ-
ence in the proportion of patients experiencing RD be-
tween plans. Generally, the occurrence of RD is also
associated with patient and treatment related factors, in
addition to dose, such as beam energy, chemotherapy, ap-
plication of bolus, etc. [22].
RP is another common side effect following PMRT.
The frequency of symptomatic RP was reportedly 1-7%
after local and regional nodes were treated to a total
dose of 45-50Gy with conventional techniques [23-25].
In the current study, only 2 (2%) patients developed grade
2 RP, indicating that IMRT technique did not increase the
risk of RP in breast cancer patients. According to reports
in literature, a diversity of factors including age, BMI,
dose-volume of normal lung, and chemotherapy contrib-
uted to the incidence of RP after PMRT [26]. Of these, the
dose-volume metrics are major predictors of the risk of
RP. Reducing the dose-volume of lung as much as possible
remains to be one of the most important objectives of
planning optimization.
Limitations and future directions
As it has been highlighted earlier, there is no consensus
whether RTOG contour guideline with contour-based
treatment planning should be applied to each patient re-
ceiving PMRT. Studies using classic field definitions have
yielded excellent local control [2-4], even if some part of
the volume may have received lower dose than expected.
Therefore, individual risk assessment and strict normal
tissue constraints should be applied when treatment
plan is to be generated based on today’s contour guide-
lines. There are certain limitations in this preliminary
study. First, we did not assess the impact of IMRT
technique on patients’ quality of life. Second, the associ-
ation between RP and IMRT plans was not analyzed due
to limited number of patients experiencing RP. Last, the
follow-up period is not long enough to observe radiation-
induced late toxicity, and biological effects of low dose ir-
radiation remains a concern for patients treated with
IMRT technique. Also, we did not perform dosimetric
comparison with standard technique as the later one is
based on clinical defined fields, with target coverage quite
different with the current contoured definition. Further
studies are therefore needed in near future to overcome
these limitations. In addition, a randomized clinical trial
comparing 3D conformal technique vs. IMRT for PMRT
might help to answer some questions about patients’ toler-
ance, quality of life, and local control, and finally to deter-
mine a better PMRT technique.
Conclusions
In this study, dosimetric analyses demonstrate that it’s feas-
ible to design IMRT plans treating the chest wall and re-
gional nodes as a whole PTV, in terms of both PTV
coverage and normal tissues sparing. The post-mastectomy
treatment with multi-beam IMRT technique was well tol-
erated by most breast cancer patients. Long-term follow-
up with larger number of patients are needed prior to wide
implementation of this technique.
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